£
Donate

We're here for you if you want to talk

0808 2080 888

[email protected]

Our partnerships with the pharmaceutical industry

Our partnerships with pharmaceutical companies allow us to deliver vital work supporting people affected by blood cancer.

The support we received in FY21 is detailed below.

Unless otherwise stated, these companies played no part in the organisation, design, or content of any of the work listed.

For more information on how and why we work with the industry, read our Policy on working with pharma.

Janssen

  • £15,000: Reducing delays to diagnosis – research undertaken by UCL
  • £30,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £480: Advisory board
  • £420: Haematology summit

Gilead

  • £11,563: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £9,824: Employability support for staff made redundant in restructure
  • £14,112: COVID-19 support 2021
  • £360: Advisory board
  • £360: Advisory board

Pfizer

  • £7,500: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £56,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

Novartis

  • £11,568: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £53,889: Clinical Trials Support Service
  • £600: Advisory board

Celgene

  • £11,563: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £39,000: Coalition – Clinical Trials

Takeda

  • £11,563: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £53,889: Clinical Trials Support Service

Bristol Myers Squibb

  • £53,889: Clinical Trials Support Service

AbbVie

  • £11,563: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £10,000: Reducing delays to diagnosis – research undertaken by UCL
  • £150: Advisory board
  • £450: Patient interviews

Roche

  • £5,000: Patient information

Jazz

  • £5,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £5,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

Sanofi

  • £7,024: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

Amgen

  • £10,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

Incyte

  • £3,602: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £7,961: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic
  • £10,000: Psychological support research

Servier

  • £1,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

AstraZeneca

  • £11,563: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

Kyowa Kirin

  • £5,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

Autolus

  • £10,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

GSK

  • £9,437: Befriending service

Chiesi

£1,000: Emergency appeal – supporting people with blood cancer during the COVID-19 pandemic

Astellas

  • £7,500: Support services 2021
Planning together by Helena Lopes

Get in touch with the Corporate Partnerships Team

Get in touch